Timothy P Heffernan

28PUBLICATIONS
390CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer cell biologyNeural networks
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 26, 2026
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.

|Apr 06, 2026
DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer.

Francesca Citron, Luca Cecchetto, Elisabetta Granato

|Nov 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung, Xinmiao Yan, Ciro Zanca

|Sep 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer.

Yongkun Wei, Minghui Liu, Er-Yen Yen

|Sep 03, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.

Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker

|Mar 05, 2025
Evolutionary fingerprints of epithelial-to-mesenchymal transition.

Luigi Perelli, Li Zhang, Sarah Mangiameli

Pageof 5

Frequent Collaborators

10 joint publications

Linghua Wang

8 joint publications

Giulio F Draetta

7 joint publications

P Andrew Futreal

7 joint publications

Alessandro Carugo